How would you approach incorporating immunotherapy in neoadjuvant treatment for GE junction and gastric cancer?

Neoadjuvant immunotherapy is a reasonable option for patients with locally advanced dMMR/MSI-H esophagogastric cancer. The recently published GERCOR NEONIPIGA study provides some preliminary data. Among the patients who underwent surgery following neoadjuvant immunotherapy, 59% of patients achieved ...